Semaglutide for Helping Opioid Recovery
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: addiction
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Opioid Use Disorder
- Interventions
- Semaglutide; Placebo
- Conditions
- Opioid Use Disorder
- Phase and size
- Phase 2 · 46 participants
- Dates
- Start 2025-06-02
Primary completion 2027-09-01 - Sponsor
- Brigham and Women's Hospital (Other)
- Last checked
- Oct 18, 2026
01Endpoints
What the trial will measure
- Cue-induced Cravings for OpioidsBaseline, 6 weeks, and 13 weeks after baseline visit
- Relapse to Illicit Opioid UseWeekly from baseline to end of study at 14 weeks
02Eligibility
Who can take part
Inclusion Criteria * English-speaking adults aged 18 or older * DSM-5 diagnosis of severe opioid use disorder (OUD) * Receiving buprenorphine ≥16 mg/day or methadone ≥70 mg/day for at least 30 days prior to enrollment * Planning to continue buprenorphine or methadone treatment throughout the study * Willing to bring buprenorphine prescriptions to visits for dose counts (if applicable) * Willing to authorize communication between the study team and their MOUD prescriber via a 42 CFR release Exclusion Criteria * Active psychosis, suicidality, homicidality, or psychiatric conditions impairing capacity to consent * Current or lifetime history of an eating disorder * BMI \<21 kg/m² * Current or lifetime diagnosis of Type 1 or Type 2 diabetes * Personal or family history of medullary thyroid carcinoma or MEN2 * GLP-1 receptor agonist use within the past 3 months or anticipated use during the study * Myocardial infarction, stroke, unstable angina, or congestive heart failure within the past 90 days * Persistently elevated BP (\>160 mmHg systolic or \>100 mmHg diastolic) during screening * History of inflammatory bowel disease, bariatric surgery, idiopathic pancreatitis, or diabetic gastroparesis * Liver function tests \>3x the upper limit of normal or eGFR \<30 * History of hypersensitivity or allergy to semaglutide * Pregnancy or breastfeeding * Anticipated participation in another investigational drug trial * Any other condition that investigators determine may interfere with participation or pose a safety concern
03Change log
Registry changes
- Primary completion dateOct 18, 2026
2026-08-31 → 2027-09-01
- Completion dateOct 18, 2026
2026-08-31 → 2027-09-15